Squarepoint’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Squarepoint’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$856K	Buy	110,977 +45,264	+69%	+$609K	﹤0.01%	3023
2026 Q1	$1.07M	Buy	+65,713	New	+$1.24M	﹤0.01%	2721
2024 Q4	–	Sell	-8,722	Closed	-$534K	–	5295
2024 Q3	$509K	Buy	+8,722	New	+$530K	﹤0.01%	3074
2024 Q2	–	Sell	-10,060	Closed	-$733K	–	4385
2024 Q1	$733K	Buy	+10,060	New	+$839K	﹤0.01%	2803
2023 Q3	–	Sell	-4,735	Closed	-$680K	–	4039
2023 Q2	$680K	Buy	+4,735	New	+$707K	﹤0.01%	2438
2022 Q3	–	Sell	-4,226	Closed	-$1.65M	–	3220
2022 Q2	$1.65M	Buy	+4,226	New	+$2.12M	0.01%	1310
2021 Q4	–	Sell	-1,703	Closed	-$363K	–	3359
2021 Q3	$363K	Buy	+1,703	New	+$362K	﹤0.01%	2154

Other funds holding LABD

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

Squarepoint's LABD Position: Q2 2026 in Review

Squarepoint increased its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 69% in Q2 2026, buying an estimated $609K and bringing the position to 110,977 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Squarepoint first reported a position in LABD in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.65M in Q2 2022. 21 funds tracked by Wall St. Rank hold LABD as of Q2 2026.

Squarepoint held 110,977 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $856K as of Q2 2026.
Squarepoint bought 45,264 Direxion Daily S&P Biotech Bear 3X ETF shares in Q2 2026, an estimated $609K.
Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3023 holding.
Squarepoint first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2021 and has held it in 7 quarters since.
Squarepoint's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $1.65M in Q2 2022.
21 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.